| Followers | 238 |
| Posts | 15503 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Saturday, November 19, 2022 10:49:25 AM
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169239751&txt2find=Maic
the DCVax-L external control arm instead used a “matching-adjusted indirect comparison” (MAIC) which comes very, very close to a one-to-one. So instead of matching the patients one-to-one, it matches by percentage each prognostic factor.
So yes, you missed that they indeed did use MAIC in the JAMA journal. You gotta look at that supplemental stuff. :)
Adjustment for Individual Patient Characteristics in ECPs
A fourth set of analyses was conducted to adjust for differences in the individual patient characteristics in the DCVax-L cohort vs. the ECPs. Propensity score matching could not be used because the ECP data were not accessible on a patient-by- patient basis, despite efforts to obtain such data. However, the percentages of specific patient characteristics were available for the ECP. Accordingly, we used Matching-Adjusted Indirect Comparison (MAIC) methodology (widely used in health economic analyses) to adjust for even small differences and re-assess survival outcomes6-8. This methodology applies a weight to each individual patient in the DCVax-L population in such a way that the sum of the weights for patients in each category for a characteristic achieves a match with the external control population. By way of example, if the external population included 50 males and 50 females and the DCVax-L population included 60 males and 40 females, the males would need to be down-weighted to achieve the required 50:50 balance. Applying a weight of 0.67 to each individual male and a weight of 1 to each individual female would achieve that balance, resulting in a new population with effectively 40 males and 40 females. When there are several characteristics to be matched (simultaneously), the mathematics by which the weights are applied to individual patients becomes more complex.
This matching was done on the characteristics of age, sex, race, MGMT methylation status, and KPS score, combined with one of either extent of resection or with residual disease. The MAIC weights required to adjust the DCVax-L cohort to match the characteristics of the external comparators were calculated in the statistical program ‘R’. These weights were checked to ensure that the characteristics of the re-weighted DCVax-L population matched those of the ECP, as well as for any outliers (particularly large weights) that could strongly influence the results of the analysis. Results between the unweighted and weighted (or matched) analyses were compared to confirm the results.
https://cdn.jamanetwork.com/ama/content_public/journal/oncology/0/coi220066supp2_prod_1668698380.82197.pdf?Expires=1671895142&Signature=M58ZRuoBIDiGCFvow2H28w5xOCYTjlat4nHXK~ojIcpb-4i~b4jPHm4f~iLZXS-0QksWPucZIRx4ik4S7YMUCblyvYJH0zz9KtKeAKhCZaPA-HZC-n1oX449Eh4~F1S1cUo1OmZGHK4DIRdcw2dVzfsA~-k~BWYtkXSniYVM4Hrin1vXDF2vb6hw-GZGpz2EpMdEX~M6qyvJoB2KuymczL-C-VyjN6PGLML5imVrliZlIgdW3fDzvq2Z-zcA0r90lJjan0fYzXWKgB0ArcrfXE6hi5brQvEGcIAxviRkGWFD~Wc1biOp~ppPdpLrgXoxoMsgMRpqOoxiI6jOJmRgvQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
Hopefully you also noted the version number on the SAP was “1”.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
